OncoMed Pharma (OMED) Issues Encouraging Update on ALPINE, PINNACLE Phase 1b Trials
Tweet Send to a Friend
OncoMed Pharma (Nasdaq: OMED) presented promising data on safety and anti-tumor activity from the ALPINE and PINNACLE Phase 1b clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
